Optimer Pharmaceuticals Reports Preliminary 2012 Gross Product Sales of $74.4 Million

Optimer Pharmaceuticals Reports Preliminary 2012 Gross Product Sales of $74.4
                                   Million

4th Quarter 2012 Gross DIFICID® Sales of $21.3 Million, Up 74.7% Over 4th
Quarter 2011 and 14.4% Above the 3rd Quarter of 2012

Optimer Launches DIFICID Co-Pay Assistance Program and Announces Price
Increase

PR Newswire

JERSEY CITY, N.J., Jan. 7, 2013

JERSEY CITY, N.J., Jan. 7, 2013 /PRNewswire/ -- Optimer Pharmaceuticals, Inc.
(NASDAQ: OPTR) today provided an update on 2012 sales for DIFICID
(fidaxomicin) tablets, an antibacterial drug launched in July 2011 for the
treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18
years of age or older in the United States. Preliminary 2012 gross product
sales in the United States and Canada totaled $74.4 million. Preliminary
gross product sales for the fourth quarter of 2012 were $21.3 million in the
United States and Canada.

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

"We ended 2012 experiencing solid growth in fourth quarter DIFICID sales after
introducing strategic initiatives to increase patient access to DIFICID and
accelerate product adoption. Treatments shipped increased by over 14% from
the third quarter," said Pedro Lichtinger, President and CEO of Optimer. "We
believe the early response to our new strategy is very encouraging. Hospital
contracting, among other efforts, appears to be having a positive impact. We
are particularly encouraged by increased DIFICID use in hospitals that our
sales force is targeting, and by the number of hospitals that are initiating a
review of DIFICID's formulary position."

Preliminary 2012 DIFICID Commercial Results

Optimer estimates DIFICID gross sales in the United States and Canada for the
three months ended December 31, 2012 were $21.3 million, an increase of over
14.4% versus the prior quarter. For the twelve months ended December 31, 2012,
preliminary gross sales increased to $74.4 million from $24.4 million in 2011.
Preliminary gross-to-net for the fourth quarter of 2012 is anticipated to be
in the 21.0% to 21.5% range. Inventory levels at wholesalers remain within
the range of 14 to 28 days of demand.

DIFICID Co-Pay Assistance Program

Optimer today announced that it is launching a Co-Pay Assistance Program for
commercially insured patients.

  oProvides up to $200 toward a patient's out of pocket cost for one
    prescription of up to 20 tablets per calendar year. Restrictions and
    conditions apply, including:

       oDoes not cover refills
       oPatients that have any part of their prescription paid by any state
         of federally funded programs, including but not limited to, Medicare,
         Medicaid, Medigap, Veterans Affairs, Department of Defense, TriCare,
         or where otherwise prohibited by law, are not eligible

DIFICID Price Increase

Optimer also announced today that it has increased the Wholesale Acquisition
Cost of DIFICID effective January 3, 2013 by approximately 5.6%. However, for
acute care inpatient hospitals the price increase will be offset through an
additional discount, keeping the net price the same. "It is important to note
that the announced 25% discount, as well as the additional offsetting
discount, is exclusive to acute care inpatient hospitals and is not available
to other classes of trade," Mr. Lichtinger continued.

Important Safety Information for DIFICID

DIFICID is contraindicated in patients with hypersensitivity to fidaxomicin or
to any of the excipients in the formulation. DIFICID should not be used for
systemic infections. Only use DIFICID for infection proven or strongly
suspected to be caused by C. difficile. Prescribing DIFICID in the absence of
a proven or strongly suspected C. difficile infection is unlikely to provide
benefit to the patient and increases the risk of the development of drug
resistant bacteria. The most common adverse reactions are nausea (11%),
vomiting (7%), abdominal pain (6%), gastrointestinal hemorrhage (4%), anemia
(2%) and neutropenia (2%).

Please visit www.DIFICID.com or call 855-DIFICID (343-4243) for full
prescribing information for DIFICID.

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a global biopharmaceutical company focused on
developing and commercializing innovative hospital specialty products that
have a positive impact on society. Optimer developed DIFICID® (fidaxomicin)
tablets, an FDA-approved macrolide antibacterial drug for the treatment of
Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and
older and is commercializing DIFICID in the US and Canada. Optimer also
received marketing authorization for fidaxomicin tablets in the European Union
where its partner, Astellas Pharma Europe, is commercializing fidaxomicin
under the trade name DIFICLIR™. The Company is exploring marketing
authorization in other parts of the world where C. difficile has emerged as a
serious health problem, including Asia. Additional information can be found at
http://www.optimerpharma.com.

Forward-Looking Statements

Statements included in this press release that are not a description of
historical facts are forward-looking statements, including without limitation
statements related to the implementation and impact of Optimer's
commercialization strategy, expansion and acceleration of DIFICID market
penetration, DIFICID sales or market potential, the hospital formulary and
patient access status of DIFICID. Words such as "believes," "would,"
"anticipates," "plans," "expects," "may," "intend," "will" and similar
expressions are intended to identify forward-looking statements. The
inclusion of forward-looking statements should not be regarded as a
representation by Optimer that any of its plans will be achieved. These
forward-looking statements are based on management's expectations on the date
of this release. Actual results may differ materially from those set forth in
this release due to the risks and uncertainties inherent in Optimer's business
including, without limitation, risks relating to: Optimer's ability to
continue driving adoption and use of DIFICID, whether healthcare professionals
will prescribe DIFICID, whether DIFICID will receive or continue to receive
reimbursement coverage from healthcare payers and government agencies, the
extent to which DIFICID will be accepted on hospital formularies and potential
delays in formulary decisions, Optimer's ability to successfully coordinate
commercialization efforts with Cubist Pharmaceuticals under its co-promotion
agreement, whether Optimer will be able to realize expected benefits under its
co-promotion agreement with Cubist, the fact that past results may not be
predictive of future results of performance, the possibility of alternative
means of preventing or treating CDAD impacting adoption and sales of DIFICID,
Optimer's ability, though its third party manufacturers and logistics
providers, to maintain a sufficient supply of DIFICID to meet demand and other
risks detailed in Optimer's filings with theSecurities and Exchange
Commission. Forward-looking statements speak only as of the date of this
release, and Optimer undertakes no obligation to update or revise these
statements, except as may be required by law.

Contacts
Optimer Pharmaceuticals, Inc.
David Walsey, Vice President, Investor Relations and Corporate Communications
(858) 964-3418

Canale Communications, Inc.
Jason I. Spark, Senior Vice President
(619) 849-6005

SOURCE Optimer Pharmaceuticals, Inc.

Website: http://www.optimerpharma.com
Website: http://www.dificid.com
 
Press spacebar to pause and continue. Press esc to stop.